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Androgen deprivation therapy reduces prostate cancer (PCa) tumour growth; however, disease relapse often ensues independently
of androgen stimulation, producing androgen-refractory tumours with increased invasion, proliferation, and malignancy. Androgens
downregulate epidermal growth factor receptor (EGFR) in normal prostate but not in PCa. Thus, loss of EGFR regulation and altered
signalling may, in part, explain the transition of prostate tumours from androgen dependent to androgen independent. Studies in
animal models, PCa cell lines, and tumour specimens suggest that androgens modulate prostate growth and function through
mechanisms that involve ‘cross-talk’ between androgen receptor (AR) and growth factor receptor signalling pathways. The objective
of this review is to discuss the paradoxical relationship between androgen regulation of EGFR in normal prostate and PCa. We
reviewed the literature from mid-1980s through 2009 to assess the relationship between androgens and EGFR function in
modulating the growth of normal prostate and PCa. Loss of androgen regulation of EGFR in PCa may be responsible for increased
tumour growth, invasion, and metastasis, with important implications on the clinical management of PCa. We advance the hypothesis
that a molecular switch, responsible for downregulating EGFR expression by androgens in the normal prostate, is either lost or
modified in PCa.
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CROSS-TALK BETWEEN ANDROGEN RECEPTORS
AND EGFR SIGNALLING PATHWAYS IN PROSTATE
Androgens modulate prostate growth and function through a
multi-step mechanism, which involves metabolism of testos-
terone (T) into 5a-dihydrotestosterone (5a-DHT) by the enzyme
5a-reductase. The more potent 5a-DHT binds to the androgen
receptor (AR). The ligand-bound AR complex undergoes mole-
cular changes known as ‘activation and transformation’, resulting
in specific interactions between the AR hormone complex and the
specific DNA enhancer element, known as androgen response
elements thought to be present in androgen-regulated genes
(Figure 1).
These complex interactions lead to upregulation of androgen-
specific target genes and downregulation of other androgen-
specific target genes to maintain homeostasis. Among the specific
target genes that are downregulated by androgen in normal
prostate tissue is the EGFR. Regulation of EGFR expression by
androgens is shown to be at the transcriptional level, both in
normal prostate tissue and prostate cancer (PCa) cell lines (Brass
et al, 1995; Ravenna et al, 1995; Nishi et al, 1996; Itoh et al, 1998;
Schwartz et al, 1998; Hammarsten et al, 2007; Pignon et al, 2009).
This regulation seems to be negatively regulated in normal cells
and upregulated in PCa, especially in androgen-independent PCa.
This suggests a defect in the molecular mechanism of action of
androgens in PCa.
The EGFR protein binds the epidermal growth factor (EGF)
and plays an important role in regulating cellular growth and
function (Traish and Wotiz, 1987; St-Arnaud et al, 1988;
Nishi et al, 1996; Itoh et al, 1998; Migliaccio et al, 2006; Bonaccorsi
et al, 2004, 2007; Le ´otoing et al, 2007). Binding EGF to EGFR
modulates cellular function by activating EGFR through autopho-
sphorylation, which results in a downstream cascade that leads to
increased cellular proliferation (Migliaccio et al, 2006). EGFR
signalling results in activation of phosphoinositol 3 kinase (PI3
kinase). The latter activates the Akt family of kinases and
signal transducer and activator of transcription (STAT), resulting
in downstream events that regulate cellular proliferation, survival,
and migration (Bonaccorsi et al, 2004, 2007; Migliaccio et al, 2006;
Le ´otoing et al, 2007) (Figure 1). Moreover, these pathways
activate the AR through phosphorylation in the absence of the
androgen ligand, thus promoting further cellular growth
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mediated via EGFR ‘‘cross-talk’’ with the AR pathway
has an important function in regulating cell growth
(Bonaccorsi et al, 2004, 2007; Migliaccio et al, 2006; Le ´otoing
et al, 2007). Evidence for such ‘cross-talk’ has been observed in
studies with androgen-dependent and androgen-refractory pros-
tate tumours.
Several studies have suggested that mutations in AR coupled
with disruptions in growth factor-activated pathways modulate AR
signalling and may be involved in the pathology of progression to
androgen-independent PCa (Scher et al, 1995). A large number of
androgen-refractory prostate tumours retain AR expression,
indicating potential activation of AR even in the absence of
androgens.
The relationship between androgens and PCa has been the
subject of intensive investigation and the literature is replete with
studies suggesting that androgens have a crucial function in
promoting PCa growth. This made androgen deprivation
therapy (ADT) the mainstay for treatment of advanced PCa.
However, ADT is of limited benefit because of disease relapse
and devastating adverse effects of androgen deprivation, especially
on the cardiovascular system (Lu-Yao et al, 2008). Recent
epidemiological and clinical studies suggested that there is no
association between T levels and risk of PCa (Roddam et al,
2008). There is no evidence to date to suggest that low
plasma T levels are protective against PCa and that physiological
levels of T increase the risk of PCa. Interestingly, T levels decline
with age and PCa incidence increases with age, suggesting that a
low T level may contribute to the development of cancer and
normal physiological T levels may be protective against PCa
(Prehn, 1999). This concept is difficult to grasp in the light of
myriad studies linking PCa growth to T on the basis of
interpretation of data in which androgen deprivation results in
regression of metastatic prostate disease. In this review, we
examined data from various studies that investigated the relation-
ship between androgens and EGFR in modulating the growth of
normal prostate tissue in animal models and in PCa to develop a
better understanding of the potential role of androgens in
regulating the growth of normal prostate and loss of this molecular
switch in PCa.
A number of studies have demonstrated that androgens
promote prostate growth in immature male animals until it
reaches its mature size, where it plateaus in the adult animal. Once
the mature size of the prostate is reached, it remains quiescent
even in the presence of stimulating physiological levels of
androgens (Simanainen et al, 2007; Wu et al, 2007). In PCa,
however, epithelial cells develop alternate mechanisms of escaping
growth inhibition in the presence of androgens and proliferate,
resulting in excessive growth. The mechanisms by which andro-
gens promote prostate cellular growth in the immature animal and
at the same time prevent excessive proliferation in the adult animal
are thought to involve regulating growth factors and their
receptors in the normal prostate (Traish and Wotiz, 1987;
St-Arnaud et al, 1988; Simanainen et al, 2007; Wu et al, 2007;
Niu et al, 2008).
Recently, several studies have demonstrated that ARs in
mature prostatic epithelium are critical for maintaining the
differentiated phenotype and overall homeostasis of the gland
(Simanainen et al, 2007; Wu et al, 2007; Niu et al, 2008).
The data suggested that epithelial AR maintains homeostasis
through reduced synthesis of proliferation-stimulatory factors or
increased synthesis of suppressors of epithelial proliferation.
The mechanisms by which AR mediates these processes are
complex and may involve specific signalling by paracrine factors
(Figure 1). These mechanisms include cross-talk between AR
signalling and growth factor receptor pathways (Bonaccorsi et al,
2004, 2007). Thus, Le ´otoing et al (2007) proposed that the
interaction between these two signalling pathways may be crucial
for the acquisition and maintenance of androgen sensitivity in the
prostate.
The EGFR signalling pathway is critical in many mammalian
cellular systems. Cell survival, growth, proliferation, and
differentiation are among the many biochemical and physiological
responses to EGFR signalling. EGFR deletion in transgenic
animals results in death in the neonatal period because of
deficiency in the development of several epithelial organs.
Increased EGFR signalling has been associated with progression
to invasion and metastasis in tumours. Several studies had related
EGFR expression and signalling in the growth of normal prostate
and PCa involving a complex signalling pathway that uses
multiple downstream modulators (Pfeil et al, 2004; Engelman
and Cantley, 2008).
Structurally, the EGFR possesses an extra-cellular domain that is
involved in specific ligand binding and receptor dimerisation, a
single transmembrane domain, and a cytoplasmic domain that
hosts intrinsic tyrosine kinase activity. On ligand binding, EGFR
forms homo- or heterodimers with other members of the same
receptor family, and thereby stimulates cytoplasmic kinase
activity, leading to auto- and trans-phosphorylation of tyrosine
residues. This phosphorylation results in conformational changes,
allowing phospho-tyrosine binding Src homology 2 (SH2)-contain-
ing adaptor proteins to bind and initiate a myriad of signalling
pathways, which includes the phospholipase C (PLC)-g activated
calcium- and PKC-mediated cascades, sarcoma viral oncogene
homologue (Ras) and its downstream ERK and JNK pathways,
STAT, as well as phosphatidylinositol-3-kinase (PI3K)/Akt.
The purpose of this review is to provide a new hypothesis to
explain the growth of Pca, irrespective of the androgen environ-
ment, because of a molecular switch in regulating EGFR expression
by androgens.
ANDROGEN REGULATION OF EXPRESSION OF EGFR
IN NORMAL PROSTATE
Castration of mature animals produced a time-dependent increase
in EGFR protein expression in the prostate (Figure 2) (Traish and
Wotiz, 1987; St-Arnaud et al, 1988). Treatment of castrated
animals with T or 5a-DHT reduced EGFR protein expression
(Traish and Wotiz, 1987; St-Arnaud et al, 1988). The down-
regulation of EGFR expression is specific to androgens, as
oestrogens and progestins did not downregulate EGFR expression.
These observations suggested that in the presence of a stimulating
environment of androgens, EGFR expression is attenuated to
reduce unnecessary excessive growth. In the absence of or because
of reduced androgen stimulation, however, EGFR protein expres-
sion is increased, probably to prevent complete prostate tissue
involution in the androgen-deprived state (Traish and Wotiz, 1987;
St-Arnaud et al, 1988). Furthermore, medical castration by
administration of luteinising hormone-releasing hormone agonist
or anti-androgen treatment also increased EGFR protein expres-
sion in the prostate (St-Arnaud et al, 1988). Nishi et al (1996)
investigated the changes in the steady-state levels of mRNAs
coding for EGFR by northern blot analysis during castration-
induced involution, and subsequent re-growth induced by
androgen in the prostate. EGFR increased after castration,
suggesting that EGFR expression is downregulated by androgens
(Nishi et al, 1996). Other studies have also shown that EGFR
mRNA expression was markedly elevated after castration of
60-day-old adult rats and T treatment reduced EGFR mRNA levels
(Itoh et al, 1998).
Recent studies also reported that androgen treatment of
castrated animals reduced EGFR protein density, diminished
epithelial and endothelial cell proliferation, and increased epithe-
lial cell apoptosis (Hammarsten et al, 2007). These results
suggested that castration-induced increase in EGFR expression
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growth and to prevent complete tissue involution (Hammarsten
et al, 2007). Interestingly, EGFR signalling is inhibited during
testosterone-induced growth, which led to growth reduction and
prevented excessive proliferation. Treatment of castrated animals
with specific monoclonal antibodies against EGFR, such as
gefitinib, which inhibit EGFR signalling, led to prostate growth
inhibition, suggesting a role for the EGFR signalling pathway in
normal prostate growth and in preventing total prostate regres-
sion. Inhibition of EGFR signalling with antibody blockade
after castration led to a further reduction in epithelial and blood
vessel weight. The authors suggested that inhibition of EGFR
signalling in castrated animals resulted in rapid prostate involu-
tion (Hammarsten et al, 2007). These data support the hypothesis
that androgens downregulate EGFR expression in normal prostate
tissue (Traish and Wotiz, 1987; St-Arnaud et al, 1988; Nishi et al,
1996).
LOSS OF REGULATION OF EGFR EXPRESSION IN PCa
BY ANDROGENS
Studies in cultured cell lines
Several studies have investigated EGFR expression in PCa cell
lines, including LNCaP, PC3, and ALVA101, with mixed results.
A number of investigators reported that androgens upregulated
EGFR in PCa cell lines (Schuurmans et al, 1989; Liu et al, 1993;
Brass et al, 1995; Ravenna et al, 1995; Hobisch et al, 2004).
Liu et al (1993) investigated the proliferation of the androgen-
dependent prostate carcinoma cell line ALVA101 in the presence
of 5a-DHT and EGF, and showed increased cell proliferation and
DNA synthesis. It was shown that EGFR ligands increased
androgen-induced mitogenesis in the androgen-dependent PCa
cell line. EGFR mRNA levels were increased in ALVA101 cells with
EGF stimulation. 5a-DHT further enhanced EGFR mRNA levels
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Figure 1 Androgen-receptor signalling in normal prostate and PCa. Free (unbound) testosterone crosses the plasma membrane phospholipid layer
presumably by simple diffusion (reaction 1). Once inside the prostate cell, testosterone undergoes metabolism by the 5a-reductase enzyme to produce the
more potent androgen 5a-DHT (reaction 2). 5a-DHT binds to the androgen receptor (AR) and causes the AR to undergo activation and transformation,
which involves dissociation from heat-shock proteins and conformational (dimerisation) and biochemical changes such as phosphorylation (reaction 3 and 4).
The activated and transformed 5a-DHT.AR complex translocates into the nucleus (reaction 5) and interacts with the androgen response element. The
5a-DHT.AR complex binds to the specific DNA response elements (reaction 6) leading to recruitment of coactivators or corepressors to regulate gene
expression (reaction 7). We postulate that in the normal prostate, the activation of AR results in downregulation of the expression of the epidermal growth
factor receptor (EGFR) mRNA (reaction 7), resulting in reduced EGFR protein synthesis (reaction 8) and the ultimate reduction of the active functional
protein (reaction 9). In PCa, we propose that either a molecular switch is turned off along this pathway, probably in regulating gene expression (reaction 7;
denoted by þblue colour), resulting in increased mRNA synthesis and increased protein synthesis and increased density of the functional EGFR (reactions 8
and 9). Further, in PCa, activation of EGFR by EGF results in signalling through a host of biochemical pathways (reactions
10–13), which result in activation of AR even in the absence of 5a-DHT. Such a switch in EGFR expression and functional activity results in tumour
androgen independence. The loss of androgen regulation concomitant with increased EGFR expression or signalling in PCa through the PI3K and MAPK
pathways results in androgen independence of tumour growth. These signalling pathways may activate the AR without ligand, culminating in androgen-
receptor signalling, leading to cellular proliferation, migration, and survival. The references for the reactions cited in Figure 1 are as follows: Reaction 1,
Heinlein and Chang, 2004; Reaction 2, Heinlein and Chang, 2004; Reaction 3, Heinlein and Chang, 2004; Reaction 4, Heinlein and Chang, 2004; Reaction 5,
Heinlein and Chang, 2004; Reaction 6, Heinlein and Chang, 2004; Reaction 7, Brass et al, 1995; Ravenna et al, 1995; Itoh et al, 1998; Schwartz et al, 1998;
Heinlein and Chang, 2004; Hammarsten et al, 2007; Pignon et al, 2009; Reaction 8, Nishi et al, 1996; Reaction 9, Traish and Wotiz, 1987; St-Arnaud et al,
1988; Reaction 10, Sugita et al, 2004; Gregory et al, 2005; Migliaccio et al, 2006; Le ´otoing et al, 2007; Zhu and Kyprianou, 2008; Recchia et al, 2009; Reaction
11, Migliaccio et al, 2006; Le ´otoing et al, 2007; Zhu and Kyprianou, 2008; Recchia et al, 2009; Reaction 12, Migliaccio et al, 2006; Le ´otoing et al, 2007; Zhu
and Kyprianou, 2008; Recchia et al, 2009; Reaction 13, Migliaccio et al, 2006; Le ´otoing et al, 2007; Zhu and Kyprianou, 2008; Recchia et al, 2009; Reaction 14,
Migliaccio et al, 2006; Le ´otoing et al, 2007; Zhu and Kyprianou, 2008; Recchia et al, 2009. Abbreviations: AKT, protein kinase B; AR, androgen receptor; ARE,
androgen response element; 5a-DHT, dihydrotestosterone; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; MEK, upstream kinases of mitogen-
activated protein kinases; mRNA, messenger RNA; P13K, phosphatidylinositol 3 kinase; STAT3, signal transducer and activator of transcription 3; TK, tyrosine
kinase. The colour reproduction of this figure is available on the html full text version of the manuscript.
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contention that increased EGFR expression mediates androgen-
induced cell proliferation, an EGFR-directed antibody was shown
to be effective in inhibiting 5a-DHT-induced mitogenesis. These
observations suggest that androgen stimulation enhanced EGFR
receptor activation with EGF in PCa cells. In contrast to that of the
normal prostate, in which androgens decrease EGFR expression, in
ALVA101 cells androgen-induced EGFR expression resulted in
increased cell division and upregulation of EGFR, thus enhancing
proliferation of PCa cells (Liu et al, 1993).
Brass et al (1995) further investigated the role of androgens in
PCa by re-introducing AR into PC3 cell lines. EGF and 5a-DHT
treatment of PC3-AR cells stimulated growth independently of
each other. When added together, they acted synergistically to
induce a greater than four-fold increase in proliferation. 5a-DHT
treatment induced a two-fold increase in EGFR transcription and
about a 50% increase in EGFR protein levels. EGF binding to EGFR
in PC3-AR cells exposed to 5a-DHT was increased, suggesting an
upregulation of EGFR expression by androgens (Figure 3).
Contrary to the above findings, Sherwood et al (1998) showed
that high levels of EGFR expression and phosphorylation were
observed only in androgen-independent human PCa cell lines, PC3
and DU 145, but not in LNCaP cell lines, which are androgen
sensitive. Cinar et al (2001) showed that human PCa cells
transfected with hAR exhibited reduced growth, invasion, and
migratory behaviour in vitro and tumour growth in vivo.
Bonaccorsi et al (2004, 2007) investigated EGF-activated signalling
in PC3 before and after transfection with AR. The authors showed
that PC3 transfected with AR had significant reduction in EGFR
autophosphorylation and PI3 kinase activation, suggesting that
androgens modulate EGFR expression and function. It was
proposed that re-constitution of the AR in androgen-independent
PCa cell lines leads to a less-malignant phenotype through an
AR-EGFR cross-talk.
300
200
100
0
013577
D
H
T
 
(
7
 
d
a
y
s
)
100
200
300
400
500
600
B
o
u
n
d
 
E
G
F
 
%
 
o
f
 
c
o
n
t
r
o
l
B
o
u
n
d
 
E
G
F
 
(
f
m
o
l
 
p
e
r
 
m
g
 
p
r
o
t
e
i
n
)
Time after castration (days)
1200
1000
800
1400
600
400
200
0
Time after castration (days)
013577
B
o
u
n
d
 
E
G
F
 
f
m
o
l
 
p
e
r
 
m
g
 
D
N
A
D
H
T
 
(
7
 
d
a
y
s
)
Figure 2 Effects of castration and androgen treatment on EGF binding
to prostatic membranes. Castrated animals (five to seven per group) were
killed at the times indicated and their prostates were removed; others were
treated with 5a-DHT (200mg daily) for 7 days and killed on day 8. Intact
animals were killed at the times indicated and their prostates were
removed. Prostates from each group were pooled and homogenised, and
membranes were prepared and assayed for EGF binding as described. The
values shown are the mean of four separate experiments. Upper panel (A):
data were expressed as femtomoles of EGF binding per mg membrane
protein. Lower panel (B): data were expressed as femtomoles per mg
DNA (adapted from Traish and Wotiz, 1987).
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Figure 3 (A) Ribonuclease protection assay using
32P-labelled antisense
EGFR and b2-microglobulin RNA riboprobes to assess the effect of 5nM
DHT on EGFR expression in stable PC3 transfectant cells. Total RNA was
isolated from PC3neo (1), PC3- hAR-Q (2), PC3-HAR-E (3), and PC3-
HAR-B (4) cells grown in the presence (þ) or absence ( )o f5n M DHT
for 48h. BP, nucleotide bp markers are
32P-end-labelled DNA fragments of
the PBR322 vector restricted with Mspl. (B) PhosphorImager analysis of
EGFR expression normalised to b2 microglobulin expression (adapted
from Brass et al, 1995).
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study the relationship between androgens and EGFR expression
and function in vitro, we must be aware that cell lines undergo
changes because of culture, storage, and experimental manipula-
tion conditions. Thus, the in vitro cell culture data must be viewed
with caution.
Studies in prostate tumour tissue specimen
Di Lorenzo et al (2002) investigated EGFR expression in PCa
tissue from 58 patients. Twenty-nine of these patients had
primary tumours and were treated with radical prostatectomy as
first-line therapy. EGFR expression was positive in 12 (41.4%)
of the 29 patients. In a second group of patients (29) with
primary tumours, the investigators first treated patients with ADT
and with anti-androgens before radical prostatectomy. EGFR
expression was found in 22 (75.9%) of 29 patients. A third group
of 16 patients with metastatic disease and hormone-refractory PCa
were found to be all positive for EGFR expression (100%). These
data suggest that ADT increased the expression of EGFR in human
PCa. The authors also demonstrated a significant association
between EGFR expression and higher Gleason scores and PSA
levels. EGFR expression significantly correlated with disease
relapse in patients. The authors further showed that 23 of 34
patients with EGFR-positive tumours had a disease recurrence
(67.0%), compared with 2 of 24 patients (8.3%) who had EGFR-
negative PCa. EGFR expression represented the only independent
parameter that was significantly associated with disease relapse
when compared with the Gleason score to T and N status and to
c-erbB-2 expression.
It should be noted that, in this study (Di Lorenzo et al, 2002), the
AR content or distribution within these tissue specimens was not
assessed in any of the tumour specimens investigated. Thus, no
direct correlation between EGFR expression and AR could be
determined from these observations. This represents a limitation
to the conclusions of this study.
The studies described above support a role for androgens in
regulating EGFR expression in the development of PCa and, more
specifically, in the progression to an androgen-independent,
hormone-refractory clinical behaviour. Hernes et al (2004) also
investigated prostatic tissue biopsies from patients before ADT
and during androgen-independent PCa development. The data
revealed that EGFR expression is significantly increased with the
development of androgen independence. Shah et al (2006)
demonstrated that EGFR expression in prostate tumour tissues
was strongly associated with the hormone-refractory status. Scher
et al (1995) showed a homogeneous staining pattern for EGFR in
17 of 19 androgen-independent refractory metastatic PCa speci-
mens. A similar increase in EGFR expression has been demon-
strated in a smaller series of PCa patients: untreated, hormone
naive (15% positive), hormone responsive (35% positive), and
hormone refractory (48% positive) (Gil-Diaz de medina et al,
1998). These observations provide bases for cross-talk between the
EGFR family and AR-activated pathways in PCa.
The results from studies with normal prostate tissues (Traish
and Wotiz, 1987; St-Arnaud et al, 1988; Nishi et al, 1996; Itoh et al,
1998; Hammarsten et al, 2007) and those described above in cell
culture studies and human prostate tumour tissue biopsies support
the concept that EGFR-stimulated growth of PCa escaped
androgen control because of a molecular switch in the cross-talk
pathway between androgens and EGFR.
DISCUSSION
In normal human prostate tissues, EGFR expression is under
negative androgen regulation. However, in PCa, EGFR expression
is upregulated, suggesting an increased expression in advanced
cancer (Di Lorenzo et al, 2002), and correlated with a high Gleason
score and tumour progression from an androgen-dependent to an
androgen-independent state (Sherwood and Lee, 1995; Syed and
Tolcher, 2003). Miyamoto et al (2008) suggested that EGFR and
bFGF were downregulated in androgen-sensitive cells expressing
AR, in which, as in androgen-independent cells, these receptors
were upregulated. Expression of EGFR has been shown to correlate
with disease relapse and/or progression to androgen-independent
disease in patients with PCa.
Cross-talk between the AR signalling pathway and growth factor
signalling may represent a key pathway during prostate PCa
progression, which may confer a survival and invasion advantage
to PCa (Ravenna et al, 1995; Miyamoto et al, 2008; Zhu and
Kyprianou, 2008). Zhu and Kyprianou (2008) reviewed the cross-
talk between growth factor receptors and AR in regulating prostate
cell differentiation, proliferation, apoptosis, and survival. These
include IL 6 R, EGFR, TGFbR1 and TGFbR2, IGFR, FGFR, and
VEGFR. Cross-talk between tyrosine kinase receptors (TKR) and
AR takes place via specific and overlapping pathways (Cai et al,
2009). Furthermore, sensitisation of the androgenic response by
multi-functional growth factor signalling pathways is thought to be
one of the mechanisms through which AR contributes to the
emergence of androgen-independent prostate tumours. The
significance of this altered cross-talk in PCa progression is of
clinical importance in understanding the pathology of the disease.
It has been suggested that regulation of EGFR by androgen is
disrupted in PCa (Russell et al (1998) and that 5aDHT treatment
increased EGFR mRNA and protein levels in LNCaP cells (Pignon
et al, 2009)). EGFR family members have a critical function in the
proliferation, migration, survival, and differentiation of target
cells. Dysregulation of signalling by ErbBs has been implicated in
the pathogenesis and progression of human cancers (El Sheikh
et al, 2003). The continued expression of AR and AR-regulated
genes in androgen-independent PCa (AI PC) suggests that
alternative signalling pathways are used to activate AR. Elements
of the AR and ErbB pathways interact, cross-over, and converge on
targets downstream of each other’s signalling cascades to promote
AI PC cell survival.
In addition to the EGFR family, an Eph receptor family of
tyrosine receptor kinases (RTK) have critical functions in
normal growth and development but were shown to be over-
expressed in a host of human cancers (Zeng et al, 2003; Surawska
et al, 2004; Fox et al, 2006; Taddei et al, 2009). Eph receptors are
thought to modulate interactions of cells within the tumour and
between tumour cells. They also regulate stroma vasculature
interaction and are implicated in PCa progression (Zeng et al,
2003; Fox et al, 2006; Taddei et al, 2009). As limited data are
available on the interaction between AR and Eph receptors in
androgen-sensitive and independent tumours, we will not discuss
this subject further in this review.
Recently, Morgentaler and Traish (2009) challenged the belief
that PCa growth is dependent on T levels and a saturation model is
proposed that accounts for the seemingly contradictory results in
human PCa studies (Morgentaler and Traish, 2009). It was
suggested that the ability of androgens to stimulate PCa growth
is limited and may involve other biochemical factors. A conceptual
framework to account for the dramatic effects of castration, as well
as the minor impact of T administration, was presented. Here, we
provide additional evidence of the potential possibility that
androgens regulate the receptor of one of the growth factors that
stimulate prostate growth, and loss of androgen regulation in PCa
may be one of the factors that contribute to the androgen
independence of PCa.
Normal prostate cells express AR, and androgens are required
for the growth and function of normal prostate. During neoplastic
transformation of prostatic epithelial cells into tumour cells,
expression of AR is retained by tumour cells, which is responsible
for androgen-dependent tumour growth. The fact that tumour cells
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growth. However, to date, no mechanism has been delineated to
suggest that androgen signalling per se is responsible for the
development of prostate tumours. Indeed, in the prostate, tumour
growth continues to depend on androgens similar to that of
normal epithelial cells. However, at some point in time, tumour
cells become androgen independent and grow in the absence of
androgens (androgen refractory). The transition from androgen
dependence to androgen independence is most often accelerated
by ADT.
Similar to the role of androgens in PCa, oestrogens regulate the
expression and activity of EGFR in breast cancer. Arpino et al
(2008) reviewed the cross-talk between oestrogen receptor (ER)
and the HER tyrosine kinase receptor family, and proposed a
mechanism of resistance to endocrine therapy in breast cancer.
Inhibition of ER expression or oestradiol deprivation or treatment
with anti-oestrogen increased EGFR expression in breast cancer
cell lines, suggesting a complex control mechanism (Lichtner,
2003; Osborne et al, 2005) An oestrogen-independent growth
ensues through alternative mechanisms during oestrogen depriva-
tion or anti-oestrogen treatment. Upregulation of EGFR in
response to oestrogen depletion was considered to be one of the
survival mechanisms of tumour cells (Yarden et al, 2001). Thus, in
ER-positive breast cancer cells, oestrogen is actively involved in
the suppression of EGFR expression, whereas in ER-negative
tumours, EGFR expression is increased. These findings suggest
that progression of breast cancer from hormone dependence to
hormone independence may involve upregulation of EGFR.
In normal prostate tissue, androgens downregulate EFGR
expression (Figure 1, reaction 7). The downregulation of EGFR
by androgens in normal cells may be responsible for the inhibition
of excessive growth in normal prostate. In PCa, however, andro-
gens seem to upregulate EGFR expression (Figure 1, reaction 7) by
a molecular switch, which remains to be defined. Loss of androgen
downregulation of EGFR expression in PCa increases EGFR
receptor expression and signalling and may produce excessive
cellular proliferation.
Transition of the prostatic epithelium from androgen depen-
dence to androgen independence may occur by clonal selection
from a heterogeneous population of androgen-dependent cells
during androgen deprivation. Alternatively, precursor stem cells
may adapt to an androgen-deprived environment and differentiate
in the absence of androgens. Another possibility is that, in the
castrated patient, adrenal androgens may represent sufficient
androgens to stimulate androgen-responsive cells (Russell et al,
1998).
One of the potential mechanisms is the activation of AR by
phosphorylation in the absence of the hormone, through the
EGFR downstream signalling pathway. Although ADT initially
reduces tumour growth, it often results in an increased EGFR
expression and subsequently increased androgen-induced
growth and development of androgen-refractory tumours and
metastasis. Thus, increased EGFR expression and signalling with
androgen deprivation may be responsible for the transition of
tumours from androgen dependence to androgen independence.
Another mechanism that may influence the expression and activity
of EGFR is homodimerisation and heterodimerisation of EGFR
with receptor subunits of members of the EGFR family (Hughes
et al, 2009; Patel et al, 2009). This reaction may be significantly
altered in PCa cells.
Several limitations of this hypothesis should be acknowledged.
First, PCa aggressiveness, androgen sensitivity, and histological
appearance exhibit marked variations and no single specific
experimental model mimicked such various facets of the clinical
disease. Second, because most of the studies were carried out with
cell lines including LNCaP, which demonstrate androgen sensiti-
vity but not androgen dependence, the concern remains that
limitations exist on interpretation of data from studies using cell
lines for understanding the molecular basis of PCa (Russell et al,
1998). Furthermore, EGF has been shown to activate the
transcriptional activity of AR by increasing the expression or
activity of AR co-activators in PCa cells and, in this way, is thought
to promote malignant progression and metastasis of advanced
PCa. Third, the cross-talk between AR and the different signalling
pathways is complex, and at present poorly understood. Given the
complexities of such interactions and the heterogeneity of PCa, a
detailed understanding of these processes is necessary to develop
appropriate therapeutic strategies for patients with PCa. Therefore,
we acknowledge that this review is focused on single gene
hypothesis, which, in view of the complexities of the molecular
interactions between AR pathways and other signalling molecules,
may limit broader interpretations.
It has been shown that overexpression of EGFR in 3T3-L1
adipocytes (200000–250000 receptors per cell) confers EGF-
inducible GLUT4-mediated glucose uptake (Van Epps-Fung, 1996).
Glucose transport and phosphorylation were increased signifi-
cantly in MDA–MB-468 breast cancer cells expressing a high
number of EGFR (Kaplan et al, 1990). In gefitinib-sensitive cell
lines, the EGFR kinase inhibitor produced a dramatic decrease in
fluoro-deoxyglucose (FDG) uptake, and glucose transport rates
were reduced by 2.6-fold. This was associated with a translocation
of glucose transporters (GLUT3) from the plasma membrane to the
cytosol. In contrast, gefitinib-resistant cells exhibited no measur-
able changes in FDG uptake, either in cell culture or in vivo
(Su et al, 2006). Recent findings (Weihua et al, 2008) have
suggested that overexpression of EGFR is associated with tumour
cell proliferation and survival, and this was attributed to
maintaining the intracellular glucose level through interaction
and stabilisation of the sodium/glucose cotransporter 1 (SGLT1).
This suggests that inhibition of the EGFR kinase activity for cancer
therapy may not provide the expected efficacy (Weihua et al,
2008). Thus, it is possible that in PCa, and in the absence of
androgens, EGFR is overexpressed in prostate tumours facilitating
glucose transport into cells by associating with and stabilising an
SGLT1 without requiring EGFR kinase activity as proposed by
Weihua et al (2008). The interaction between EGFR and SGLT1
may represent a novel mechanism of adaptation by cancer cells to
meet energy demand for cellular growth and suggests that EGFR
contributes to increased cell survival and metastasis independent
of the EGFR signalling pathway. This novel mechanism may
be exploited in targeting EGFR expression without targeting
the kinase per se to develop new treatment strategies for the
management of androgen-independent PCa.
In view of this novel concept, an increased EGFR expression
in PCa because of loss of androgen-dependent regulation
would enhance tumour growth, invasion, and metastasis due to
increased EGFR in tumour cells. Thus, the interplay between AR
and EGFR in regulating cellular growth of the prostate is of
paramount importance. Any molecular switch that disrupts the
regulation of EGFR expression by androgens and the mechanisms
involved in mediating the cross-talk between AR and EGFR
would result in loss of cellular regulation and promote uncon-
trolled growth. The loss of regulation of EGFR expression
by androgens in PCa represents an important pathway in
cellular growth, invasion, and metastasis. A better understanding
of this regulation may represent a target for therapeutic manage-
ment of PCa.
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